SWOG clinical trial number
S8814B
Molecular Predictors of Outcome on CAF plus Tamoxifen versus Tamoxifen Alone in Postmenopausal Women with Node-Positive, Receptor-Positive Breast Cancer - A Transcriptome Expression Analysis of SWOG S8814
Closed
Abbreviated Title
Molecular Predictors of Outcome TM Study
Research committees
Breast Cancer
Other Clinical Trials
SWOG Clinical Trial Number
CTSU-A012303
Shortstop-HER2: Shortened Duration of Adjuvant Therapy in Patients with Early-Stage HER2+ Breast Cancer who Achieve PCR After Neoadjuvant Chemotherapy with HER2 Blockade
Research Committee(s)
Breast Cancer
Activated
07/25/2025
Open
SWOG Clinical Trial Number
CTSU-A012301
LoTam: A Randomized, Phase III Clinical Trial of Low-Dose Tamoxifen for Selected Patients with Molecular Low-Risk Early-Stage Breast Cancer
Research Committee(s)
Breast Cancer
Activated
02/05/2025
Open
Phase
SWOG Clinical Trial Number
S2206
A Randomized trial of neoadjuvant durvalumab plus chemotherapy versus chemotherapy alone for Adults with MammaPrint Ultrahigh (MP2) hormone receptor (HR) positive /Human Epidermal Growth Factor receptor (HER2) negative stage II-III breast cancer
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
10/30/2023
Accrual
30%
Open
Phase